Clinical trial
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood…
NCT00025038 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00025038 |
|---|---|
| Title | Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia |
| Official title | Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Juvenile Myelomonocytic Leukemia |
| Intervention type | Biological, Drug, Other, Procedure, Radiation |
| Interventions | tipifarnib, isotretinoin, fludarabine phosphate, cytarabine, radiation therapy, cyclophosphamide, anti-thymocyte globulin, allogeneic bone marrow transplantation, double-unit umbilical cord blood transplantation, umbilical cord blood transplantation and 1 more |
| Enrollment | 100 |
| Start date | Jun 1, 2001 |
| Primary completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: